IDEXX jumps after Q1 beat and higher 2026 EPS outlook to $14.45–$14.90
IDXX•IDEXX Laboratories shares are higher after the company reported first-quarter 2026 results and raised its full-year 2026 EPS outlook to $14.45–$14.90. The updated forecast reflects expectations for higher revenue, comparable operating-margin expansion, and updated foreign-exchange assumptions.
1. What’s moving the stock
IDEXX Laboratories (IDXX) is moving higher following its first-quarter 2026 earnings release and an upward revision to its full-year outlook. The company lifted its 2026 EPS guidance to $14.45–$14.90, citing expectations for increased revenue, comparable operating-margin expansion, and updated foreign-exchange estimates.
2. Key numbers and guidance reset
The raised EPS range represents a modest but meaningful guide-up that signals confidence in execution despite an uneven demand backdrop in parts of the veterinary channel. The company’s 2026 outlook framework continues to incorporate pricing and margin levers alongside FX assumptions, with investors focusing on whether IDEXX can sustain premium growth and profitability relative to broader animal-health spending trends.
3. What investors are watching next
After the earnings-driven move, attention shifts to the durability of companion-animal diagnostics utilization and any incremental signs that clinic traffic pressure is stabilizing. Investors are also watching for follow-through on margin performance and whether IDEXX can keep translating revenue growth into higher earnings power through the rest of 2026.
